Introduction
Biologics — complex molecules like monoclonal antibodies (mAbs), vaccines, and insulin — are reshaping modern medicine, treating chronic diseases from cancer to rheumatoid arthritis. Global biologics market is projected to exceed $700 billion by 2030. India, recognising this strategic opportunity, announced the Biopharma SHAKTI strategy (₹10,000 crore outlay) in Union Budget 2026 to boost domestic biologics and biosimilars production. However, the sector faces a foundational challenge: traditional animal models poorly predict human biological responses, making next-generation human-relevant testing systems both a scientific necessity and a policy priority.
Key Concepts
Biologics — Large, complex molecules produced by living cells. Examples: monoclonal antibodies (mAbs), insulin, CAR T-cell therapy, vaccines. Used to treat cancer, autoimmune disorders, and chronic diseases.
Biosimilars — Generic versions of biologics, reverse-engineered after the original patent expires. Cheaper, but require rigorous regulatory approval due to complexity.
Non-Animal Methodologies (NAMs) — Bioengineered, human-cell-derived testing systems used as alternatives to animal models.
| NAM Type | Description | Example Use |
|---|---|---|
| Organoids | Miniature organ-like 3D structures from stem cells | Drug toxicity testing |
| Organ-on-a-chip | Microfluidic devices mimicking organ function | CAR T-cell therapy trials |
| 3D Bioprinting | Printed tissue models using human cells | Cancer drug testing |
Why Animal Models Fail for Biologics
Biologics bind to specific human receptors that may be absent or functionally different in animals. Two landmark failures illustrate this:
The Northwick Park Tragedy (2006) saw six healthy volunteers develop multiple organ failure during Phase I trials of theralizumab (a mAb for rheumatoid arthritis). Preclinical tests on rhesus monkeys showed no such reaction — because their immune cells respond differently from human cells.
In 2022, semorinemab failed in Phase II trials among 457 Alzheimer's patients despite effectiveness in mouse models, further exposing the predictive gap of animal testing for biologics.
As Prof. Sarfaraz Niazi (University of Illinois) notes: "Biologics bind to particular receptors in the human body. But those receptors are sometimes missing or function differently in animals, which makes animal testing less predictive."
Non-Animal Methodologies: Promise and Progress
Global Momentum
The UK published a roadmap in 2024 to phase out animal experiments and promote NAM adoption. The U.S. FDA has also begun accepting NAM data for certain drug approvals.
India's Regulatory Step
The New Drugs and Clinical Trials (Amendment) Rules, 2023 formally promotes NAM use in novel drug development — a significant regulatory shift.
Scientific Validation
A 2024 study in Cell demonstrated a breast cancer-on-chip model to test CAR T-cell therapy against solid tumours, recreating the tumour microenvironment (abnormal blood vessels, T-cell penetration barriers) without using animals.
Economic Case
A 2019 analysis in Drug Discovery Today estimated organ-on-chip technologies could:
- Reduce overall drug development costs by 10–26%
- Cut lead optimisation time by 19%
Challenges
1. Translation Gap Over 90 academic labs in India work on NAMs, but innovation is not converting into industry-ready products. Standardised protocols, documentation, and regulatory-accepted validation frameworks are absent.
2. Funding and Infrastructure Sustained capital investment and lab-scale-to-industry-scale infrastructure are lacking. Biopharma SHAKTI's ₹10,000 crore could address this if directed toward platform-building rather than single-product development.
3. Entrepreneurship and Investment Deficit As Narendra Chirmule (CEO, SymphonyTech Biologics) observes: "Investors are not well versed in the risks and potentials of the biologics industry" — limiting private capital flow into the sector.
4. Patent Evergreening Original biologic manufacturers extend market exclusivity through minor reformulations. Example: trastuzumab (cancer drug) — IV form approved in 2000, but a new subcutaneous formulation patent delayed biosimilar entry until 2018, an 18-year exclusivity window.
5. Regulatory Lag CDSCO (India's apex drug regulator) biosimilar guidelines are still in draft form. Regulatory confidence in independently validated NAM data remains limited, slowing both NAM adoption and biosimilar approvals.
Biopharma SHAKTI: Key Dimensions
| Dimension | Detail |
|---|---|
| Announced | Union Budget 2026 |
| Outlay | ₹10,000 crore |
| Focus Areas | Biologics production, biosimilars, NAM integration |
| Nodal Support | DBT, ICMR, AIC-CCMB (CPHMS) |
| Regulatory Interface | CDSCO biosimilar guidelines (under revision) |
Conclusion
India's biologics and biosimilars sector holds strategic importance — for public health, economic self-reliance, and global pharmaceutical competitiveness. Biopharma SHAKTI signals the right intent, but intent must be matched with regulatory clarity, standardised NAM validation frameworks, and a biosimilar-friendly IP environment that addresses patent evergreening. The convergence of human-relevant science and forward-looking policy is what will determine whether India becomes a credible global biologics hub — or remains a downstream market for innovations developed elsewhere.
